CARMAT : Invest Securities upgrades to buy
Nevertheless, growth is encouraging and many indicators are positive from a medium-term perspective. In 2025, the Group anticipates at least a further doubling of sales, which is below our expectations", moderates the analyst.
While acknowledging that the current valuation remains heavily impacted by delays and poor financial visibility, he believes that "the market should welcome the clinical milestones expected in 2025, and in particular the EFICAS results at the end of 2025".
Copyright (c) 2025 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.
Go to the original article.
Contact us to request a correction